Sobi acquires CTI BioPharma and its JAK inhibitor for $1.7B.
Swedish pharma company Sobi is acquiring CTI BioPharma for $1.7 billion, with the main attraction being the JAK inhibitor Vonjo, which received FDA accelerated approval last year for a rare bone marrow cancer. Sobi is paying an 89% premium to CTI's closing stock price on Tuesday. Sobi specializes in rare diseases.